Compare · NHF vs PBIO
NHF vs PBIO
Side-by-side comparison of NexPoint Strategic Opportunities Fund (NHF) and Pressure BioSciences, Inc. (PBIO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NHF and PBIO operate in n/a (n/a), so they compete in similar markets.
- NHF carries a market cap of $542.3M.
NexPoint Strategic Opportunities Fund
NexPoint Strategic Opportunities Fund is a closed ended balanced mutual fund launched by Highland Capital Management, L.P. It is managed by Nexpoint Advisors, L.P. The fund invests in the fixed income markets of the United States. It invests in companies across broadly diversified sectors to construct its portfolio. The fund typically invests in senior loans, secured and unsecured floating and fixed rate loans, bonds, debt obligations of stressed, distressed, and bankrupt issuers, mortgage-backed securities, asset-backed securities, and collateralized debt obligations with a primary focus on below investment grade debt and equity securities. It employs a quantitative analysis to create its portfolio. The fund benchmarks the performance of its portfolio against the Dow Jones Credit Suisse Hedge Fund and the HFRX Global Hedge Fund. It was formerly known as NexPoint Credit Strategies Fund. NexPoint Strategic Opportunities Fund was formed on June 1, 2006 and is domiciled in the United States.
Pressure BioSciences, Inc.
Pressure BioSciences, Inc. develops and sells pressure-based platform solutions in the Americas, Europe, Asia, Africa, and Australia. Its pressure cycling technology (PCT) technology uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control the actions of molecules in biological samples, including cells and tissues from human, animal, plant, and microbial sources. The company offers Barocycler instrumentations comprising Barocycler 2320EXT, Barocycler HUB880, Barocycler HUB440, and The Shredder SG3. It also distributes cell disruption equipment, parts, and consumables. In addition, the company offers Barocycler consumable products, such as PCT MicroTubes, PCT MicroCaps, PCT-Micro Pestle, and pressure used to lyse samples for extraction tubes, as well as application specific kits, including consumable products and reagents. It serves researchers at academic laboratories, government agencies, biotechnology companies, pharmaceutical firms, and other life science institutions. Pressure BioSciences, Inc. has collaborations with RedShiftBio Inc.; Inova Schar Cancer Center; NYU; Leica Microsystems, GmbH; Steinbeis Centre for biopolymer analysis and biological mass spectrometry; The Ohio State University; University of Delaware; and Cedars Sinai Medical Center. The company was formerly known as Boston Biomedica, Inc. Pressure BioSciences, Inc. was incorporated in 1978 and is based in South Easton, Massachusetts.
Latest NHF
- NexPoint Extends Offer to Purchase Shares of United Development Funding IV (UDFI)
- NexPoint Extends Offer to Purchase Up to All Shares of United Development Funding IV (UDFI)
- NexPoint Extends Offer to Purchase Up to All Shares of United Development Funding IV (UDFI)
- NexPoint Extends Offer to Purchase Up to All Shares of United Development Funding IV (UDFI)
- NexPoint Extends Offer to Purchase Up to All Shares of United Development Funding IV (UDFI)
- NexPoint Extends Offer to Purchase Up to All Shares of United Development Funding IV (UDFI)
- NexPoint Extends Offer to Purchase Up to All Shares of United Development Funding IV (UDFI)
- NexPoint Extends Offer to Purchase Up to All Shares of United Development Funding IV (UDFI)
- NexPoint Extends Offer to Purchase Up to All Shares of United Development Funding IV (UDFI)
- NexPoint Extends Offer to Purchase Up to All Shares of United Development Funding IV (UDFI)
Latest PBIO
- SEC Form 10-Q filed by Pressure BioSciences, Inc.
- Director Peterson Jeffrey N acquired $1,670 worth of shares (59,652 units at $0.03), increasing direct ownership by 72% to 142,084 units (SEC Form 4)
- Director Urdea Michael S acquired $404 worth of shares (14,429 units at $0.03), increasing direct ownership by 44% to 47,588 units (SEC Form 4)
- President, CEO Schumacher Richard T acquired $641 worth of shares (22,878 units at $0.03), increasing direct ownership by 38% to 82,967 units (SEC Form 4)
- Director Lazarev Alexander V acquired $528 worth of shares (18,863 units at $0.03), increasing direct ownership by 102% to 37,400 units (SEC Form 4)
- SEC Form 10-Q filed by Pressure BioSciences, Inc.
- SEC Form NT 10-Q filed by Pressure BioSciences, Inc.
- Pressure BioSciences, Inc. filed SEC Form 8-K: Other Events
- Pressure BioSciences, Inc. filed SEC Form 8-K: Leadership Update
- Pressure BioSciences, Inc. to Host Business and Financial Update on Thursday, June 20th at 4:30pm ET